News

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular ...
Keros Therapeutics Announces Review of Strategic Alternatives
Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of ProcessLEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros ...
Morningstar6d
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
“We are initiating a process to explore alternatives available to the company to maximize stockholder value, which include finding a strategic partner with the resources to develop what we ...